ducovest

MDT:NYE-Medtronic PLC (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 81.6

Change

+0.06 (+0.07)%

Market Cap

USD 103.90B

Volume

3.32M

Analyst Target

USD 115.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

Company Website : https://www.medtronic.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.51 (+0.44%)

 USD 200.50B
ZBH Zimmer Biomet Holdings Inc

-0.05 (-0.05%)

 USD 21.51B
STE STERIS plc

+0.04 (+0.02%)

 USD 21.31B
GMED Globus Medical

+0.95 (+1.14%)

 USD 11.25B
SNN Smith & Nephew SNATS Inc

+0.02 (+0.08%)

 USD 10.75B
PEN Penumbra Inc

+0.18 (+0.07%)

 USD 9.31B
BIO Bio-Rad Laboratories Inc

+0.86 (+0.26%)

 USD 9.17B
BIO-B Bio-Rad Laboratories Inc

N/A

 USD 9.16B
GKOS Glaukos Corp

+1.45 (+0.96%)

 USD 8.32B
INSP Inspire Medical Systems Inc

+2.80 (+1.50%)

 USD 5.63B

ETFs Containing MDT

CYBG:LSE VanEck Bionic Engineering.. 9.75 % 0.00 %

N/A

 N/A
CIB0:XETRA VanEck Bionic Engineering.. 9.50 % 0.00 %

N/A

 USD 4.87M
UMDV:SW iShares US Medical Device.. 9.28 % 0.00 %

N/A

 N/A
FLV American Century ETF Trus.. 5.39 % 0.00 %

+0.14 (+0.43%)

 N/A
PCIG Litman Gregory Funds Trus.. 5.31 % 0.00 %

+0.04 (+0.43%)

 USD 0.03B
FHI:CA CI Health Care Giants Cov.. 5.07 % 0.75 %

N/A

 CAD 0.08B
UTRN Vesper U.S. Large Cap Sho.. 4.07 % 0.00 %

+0.05 (+0.43%)

 USD 0.02B
DIVP The Advisors’ Inner .. 3.81 % 0.00 %

+0.04 (+0.43%)

 USD 0.01B
DXQ:CA Dynamic Active Enhanced Y.. 2.53 % 0.00 %

N/A

 N/A
GDVD 2.46 % 0.00 %

N/A

 N/A
PUD.B:CA 1.85 % 0.66 %

N/A

 N/A
TWAR 1.11 % 0.00 %

N/A

 N/A
JIGB 0.45 % 0.14 %

N/A

 N/A
SCHZ Schwab U.S. Aggregate Bon.. 0.01 % 0.04 %

+0.03 (+0.43%)

 USD 8.47B
BLV Vanguard Long-Term Bond I.. 0.00 % 0.07 %

+0.02 (+0.43%)

 N/A
DTN 0.00 % 0.38 %

N/A

 N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.26 (+0.43%)

 N/A
JDIV J.P. Morgan Exchange-Trad.. 0.00 % 0.12 %

+0.13 (+0.43%)

 N/A
VSDA VictoryShares Dividend Ac.. 0.00 % 0.35 %

+0.09 (+0.43%)

 USD 0.24B
AIIQ 0.00 % 0.79 %

N/A

 N/A
GDNA 0.00 % 0.00 %

N/A

 N/A
INAU 0.00 % 0.00 %

N/A

 N/A
HWF:CA 0.00 % 0.00 %

N/A

 N/A
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.00 %

N/A

 CAD 0.05B
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

-0.06 (0.43%)

 N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.06 (0.43%)

 N/A
SICK 0.00 % 0.95 %

N/A

 N/A
VCLT Vanguard Long-Term Corpor.. 0.00 % 0.07 %

+0.06 (+0.43%)

 USD 15.44B
VCSH Vanguard Short-Term Corpo.. 0.00 % 0.07 %

+0.05 (+0.43%)

 USD 35.42B
YLD Principal Active High Yie.. 0.00 % 0.65 %

N/A

 USD 0.27B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

N/A

 CAD 0.21B
XUKS:LSE db x-trackers FTSE 100 Sh.. 0.00 % 0.00 %

N/A

 USD 7.29M
OUFH:XETRA 0.00 % 0.00 %

N/A

 N/A
ABEQ Absolute Core Strategy ET.. 0.00 % 0.00 %

+0.06 (+0.43%)

 USD 0.09B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

N/A

 CAD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.95% 48% F 34% F
Dividend Return 2.54% 86% B+ 40% F
Total Return 1.59% 52% F 30% F
Trailing 12 Months  
Capital Gain -1.37% 48% F 34% F
Dividend Return 2.53% 86% B+ 40% F
Total Return 1.16% 55% F 29% F
Trailing 5 Years  
Capital Gain -28.01% 42% F 20% F
Dividend Return 10.82% 100% F 34% F
Total Return -17.19% 46% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -2.87% 35% F 20% F
Dividend Return -0.36% 39% F 19% F
Total Return 2.52% 100% F 57% F
Risk Return Profile  
Volatility (Standard Deviation) 19.66% 94% A 56% F
Risk Adjusted Return -1.82% 39% F 19% F
Market Capitalization 103.90B 96% N/A 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.